AIMC Topic: Adalimumab

Clear Filters Showing 1 to 5 of 5 articles

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.

The Lancet. Rheumatology Aug 21, 2023
BACKGROUND: An adalimumab biosimilar with an interchangeability designation could increase access to effective treatment for more patients. We aimed to assess the interchangeability of adalimumab biosimilar PF-06410293 (adalimumab-afzb) and reference...
Arthritis, Rheumatoid Male Methotrexate Middle Aged Humans Female Adalimumab Biosimilar Pharmaceuticals
View on PubMed DOI

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.

PLoS computational biology Jun 2, 2023
Cycling of biologic or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients due to non-response is a problem preventing and delaying disease control. We aimed to assess and validate treatment res...
Male Deep Learning Humans Female Adalimumab Antirheumatic Agents Arthritis, Rheumatoid Prednisone Biological Products
View on PubMed DOI

Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers.

Arthritis & rheumatology (Hoboken, N.J.) Nov 4, 2019
OBJECTIVE: Accurate prediction of treatment responses in rheumatoid arthritis (RA) patients can provide valuable information on effective drug selection. Anti-tumor necrosis factor (anti-TNF) drugs are an important second-line treatment after methotr...
Normal Distribution Etanercept Outcome Assessment, Health Care Antirheumatic Agents Certolizumab Pegol Reproducibility of Results Regression Analysis Infliximab Male Predictive Value of Tests Genetic Markers Methotrexate Severity of Illness Index Polymorphism, Single Nucleotide Adalimumab Arthritis, Rheumatoid Treatment Outcome Middle Aged Humans Tumor Necrosis Factor-alpha Machine Learning Female
View on PubMed DOI

Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis.

PloS one Apr 4, 2019
Myasthenia gravis (MG) is an autoimmune disease. In recent years, considerable evidence has indicated that Gene Ontology (GO) functions, especially GO-biological processes, have important effects on the mechanisms and treatments of different diseases...
Myasthenia Gravis Databases, Pharmaceutical Pharmacogenomic Testing Etanercept Genetic Association Studies Organometallic Compounds Databases, Genetic Gene Ontology Glucosamine Humans Thalidomide Carnosine Gene Regulatory Networks Immunosuppressive Agents Zinc Compounds Adalimumab Drug Repositioning
View on PubMed DOI

Deep learning conventional learning algorithms for clinical prediction in Crohn's disease: A proof-of-concept study.

World journal of gastroenterology Oct 14, 2021
BACKGROUND: Traditional methods of developing predictive models in inflammatory bowel diseases (IBD) rely on using statistical regression approaches to deriving clinical scores such as the Crohn's disease (CD) activity index. However, traditional app...
Algorithms Retrospective Studies Female Humans Infliximab Crohn Disease Deep Learning Tumor Necrosis Factor Inhibitors Cohort Studies Adult Adalimumab Male
View on PubMed DOI
Popular Topics
Recent Journals